Trillium Therapeutics Inc (NASDAQ: TRIL) was a big gainer in yesterday’s trading session, and closed the day with gains of 93.96%. This came after the company announced progress on its TTI-621 and TTI-622 clinical programs. The CEO, Jan Skvarka announced that, the